SAHPRA has registered pALD — the first-ever 3-in-1 fixed-dose dispersible tablet (ABC/3TC/DTG 60/30/5mg) for children living with HIV. This strawberry cream-flavoured, once-daily tablet replaces the need for separate pDTG and pABC/3TC formulations, making treatment simpler for caregivers and children alike. Here's what you need to know: → For children weighing 2kg to 20kg → Once-daily dosing, dispersed in water → Phase 1 rollout begins February–June 2026 → DTG-rifampicin interaction still applies — remember to add an extra DTG dose for children on TB treatment Review the full NDoH circular for dosing tables, transition timelines, and procurement details.